Efficacy of acupuncture for chronic prostatitis/chronic pelvic pain syndromes: study protocol for a randomized, sham acupuncture-controlled trial

Zongshi Qin1,2, Zhiwei Zang3, Jiani Wu1, Jing Zhou1,2 and Zhishun Liu1*

Abstract

Background: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) affects many adult men worldwide. The currently available therapies offer little or no proven benefit for CP/CPPS. We designed this study to assess the efficacy of acupuncture therapy for the treatment of CP/CPPS.

Methods: This study is designed as a randomized, sham acupuncture-controlled trial. We will compare patients with CP/CPPS in an acupuncture group and a sham acupuncture group. Sixty-eight patients will be randomly allocated to receive acupuncture or sham acupuncture. The treatments will consist of 30-min sessions, three times weekly, for 8 weeks. The primary outcome measure is change in the weekly mean National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total score from baseline through the 8-week treatment period. Secondary measures include the NIH-CPSI subscale scores, the total International Prostate Symptom Score (IPSS), patients' response rate, and patient satisfaction after treatment. We will also assess changes in the NIH-CPSI total score from baseline at the 20th and 32nd week of follow-up.

Discussion: This is a randomized, sham-controlled trial of acupuncture treatment for CP/CPPS. The results of this trial will provide more evidence on whether acupuncture is efficacious for treating CP/CPPS.

Trial registration: Clinical Trials.gov NCT02588274

Keywords: Chronic prostatitis/chronic pelvic pain syndrome, Acupuncture, Efficacy, Randomized controlled trial

Background

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common prostatic syndrome with a worldwide prevalence of 2% to 10% in adult men [1–3]. Based on a survey in China, the prevalence of CP/CPPS-like symptoms among Chinese men is 4.5% [4]. CP/CPPS can present with a wide range of clinical manifestations; the main symptoms include urogenital pain, lower urinary tract symptoms, psychological issues and sexual dysfunction [5]. Compared with other urological conditions, the aetiologic factors of CP/CPPS are unclear, and its pathophysiological mechanisms are still poorly understood. It is hypothesized that inflammation or abnormal activity of the pelvic nerve and muscle play important roles in this disease [6]. According to the consensus guidelines, there is still no standard treatment for CP/CPPS; as a result, individualized therapy and symptom-based treatment approaches are recommended [5]. The interventions for CP/CPPS include medication (alpha-adrenergic antagonists, antibiotics, pain pharmacotherapies, 5-alpha-reductase inhibitors, and phytotherapy), physiotherapy (biofeedback, acupuncture) and surgical intervention [7–10]. Drugs such as alpha-adrenergic antagonists and antibiotics have been considered the initial treatment options for CP/CPPS, but in most cases, the administration of a single drug does not relieve multiple symptoms [5]. Hence, other approaches to prevent and ameliorate CP/CPPS symptoms are considered essential. Acupuncture may be a...
Currently underestimated option for CP/CPPS treatment. Based on prior research by Lee et al., acupuncture may relieve the pain-related symptoms of CP/CPPS [11]. Thus far, although several well-designed randomized controlled trials (RCTs) related to acupuncture for the treatment of CP/CPPS have been published [12–15], the recommendations for CP/CPPS in current guidelines remain at level 5 (the lowest level) [5]. Therefore, we designed this trial to further assess the efficacy of acupuncture for treating CP/CPPS.

Methods/design
Aim
The aim of this study is to evaluate the efficacy of acupuncture in CP/CPPS patients.

Design
This study is a multi-centre, sham-controlled, randomized trial of acupuncture for the treatment of CP/CPPS that will be conducted in the Guang’anmen Hospital of China Academy of Chinese Medical Sciences and Yantai Hospital of Traditional Chinese Medicine from November 2015 to May 2017. All of the patients will be asked to sign an informed consent form prior to randomization. Blinded evaluators and statisticians will manage all data. We developed this protocol according to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist [16]. This trial protocol has been approved by the Research Ethical Committee of Guang’anmen Hospital of China Academy of Chinese Medical Sciences and Yantai Hospital of Traditional Chinese Medicine, and it has been registered under the identifier NCT02588274 at ClinicalTrials.gov in the USA. Figure 1 provides a study flow chart.

Participants
Sixty-eight patients will be recruited from the Guang’anmen Hospital of Chinese Academy of Chinese Medical Sciences and Yantai Hospital of Traditional Chinese Medicine.

Inclusion criteria
Patients must meet the diagnostic criteria from the NIH CP/CPPS consensus [17], including the following:

1. History of pain perceived in the prostate region and absence of other lower urinary tract pathology for a minimum of three of the past 6 months. In addition, any associated lower urinary tract symptoms, sexual function, and psychological factors should be addressed. Physical examinations, urine analyses, and urine cultures will be performed for all subjects.
2. Age 18 to 50 years
3. NIH Chronic Prostatitis Symptom Index (NIH-CPSI) total score ≥ 15 (scale 0–43, with 0 meaning no symptoms).

Exclusion criteria
1. Other urologic diseases, such as acute prostatitis, bacterial prostatitis, benign prostatic hyperplasia (BPH), prostate cancer, urinary tuberculosis, and urinary tract infection. (The 2-glass test will be performed in patients with urinary tract symptoms using their voided bladder 2 (VB2) and VB3, which can provide fairly accurate results and is easy to perform [18].)
2. Serious or acute diseases involving the heart, liver, kidney or blood.
3. Patients receiving acupuncture or medication (including alpha blockers or pain killers) in the week prior to the baseline assessment.

Recruitment procedures
We will recruit the participants using advertisements in newspapers, on television, and on the Internet. Prospective participants will obtain a good understanding of the trial by reading the advertisement, which will include a brief introduction of the population needed, the contact information of the researchers, and details of the acupuncture intervention and of the comparison (all participants will be informed that there are two acupuncture groups, i.e., a traditional acupuncture group and a sham acupuncture group, in which blunt needles are used to stimulate the acupoint skin, and that they have a 50 % chance of being allocated into either of the two groups). If the patient is eligible and interested in the trial, they will be invited to consult with the study doctors; after the doctors have provided a diagnosis, the patients will be recruited. All of the participants will be required to sign an informed consent form before the trial that will include an introduction of CP/CPPS, the inclusion and exclusion criteria of the trial, and an introduction to the interventions. In addition, participants have the right to withdraw from the trial at any time.

Randomization
After the participants have completed a baseline evaluation and met the selection criteria, one research assistant, uninvolved with the treatment and data collection, will be responsible for randomly grouping the participants. The acupuncturists will be blinded to the process of randomized assignment. The random sequence will be generated by the Institute of Clinical Pharmacology affiliated to Guang’anmen Hospital of China Academy of Chinese Medical Sciences. Randomization numbers using a block of four will be sealed in a scheduled...
computer-generated opaque randomization envelope. To ensure that randomization is successfully implemented, the patient’s sequence number will be written outside of the envelope, and a paper-written group name will be inside the envelope. All envelopes will be numbered sequentially. The envelopes will be delivered according to the patients’ screening sequence numbers. Finally, the acupuncturist will be informed of the random numbers and the group assignment by telephone or e-mail.

**Interventions and comparison**

**Treatment group**

According to records in the ancient Traditional Chinese Medicine work *Huangdi Neijing*, acupuncture points belonging to bladder meridian (BL) have a noticeable effect on urinary disease. Furthermore, spleen meridian (SP), kidney meridian (KI), and liver meridian (LR) intersect at Sanyinjiao (SP 6), one of the most frequently used acupuncture points for urogenital disease [19, 20]. In addition, the treatment was based on the theory of neuroanatomy [10, 21, 22] and consensus among acupuncture experts in Guang’annmen Hospital. Therefore, we chose the following acupuncture points: Zhongliao (BL 33), Shenshu (BL 23), Huiyang (BL 35), and Sanyinjiao (SP 6) (Table 1). After the patients are relaxed and in a prone position, acupuncturists will use 75% alcohol pads to sterilize the skin around the acupuncture points and then insert steel needles (Huautuo, Suzhou, China 0.3 mm*40 mm/0.3 mm*75 mm) into the acupuncture points. For bilateral Zhongliao (BL 33), the needle will be inserted approximately 50–60 mm with a 45-degree angle. For Huiyang (BL 35), the needle will be inserted approximately 50–60 mm. For Shenshu (BL 23) and Sanyinjiao (SP 6), the needles will be inserted vertically to a depth of 25–30 mm. Acupuncturists will twirl at BL23, BL35 and SP 6 to achieve and enhance the sensation of aches, heaviness or numbness in the area surrounding the inserted needle (known as de qi), and the manipulations will be performed a total of three times during 1 session (every 10 min). For bilateral BL 33, which are located in the 3rd posterior sacral foramina, needles will be inserted without lifting or rotating based on the characteristics of the points. There are 24 treatment sessions after baseline that occur three times a week, and the participants will receive a 30-min treatment each session.

**Control group**

The control group will receive sham acupuncture at the same acupuncture points as the treatment group. The sham needle with a blunt tip used in the control group is similar to the Streitberger needle (Fig. 2 provides a diagram to illustrate the sham acupuncture applied in this trial) [23]. Acupuncturists will gently lift, thrust, and twist the sham needles to simulate the treatment procedure, thus blinding the patients to the intervention. Each acupuncture point will undergo the same twirling motion as the acupuncture group. The duration and
frequency of the sessions will be the same as in the acupuncture group. To ensure blinding, the investigators will make appointments with each participant on alternate days to prevent crosstalk between groups. To test the success of the blinding, the participants will be asked to answer the following question after the 4th week treatment: “Do you think you received traditional acupuncture (A) or sham acupuncture (blunt needles used to stimulate the acupoint skin) (B)?” The participants can answer “A”, “B” or “unclear” (these two interventions will be demonstrated before the treatment, and all participants will have a good understanding of both interventions). Any medication usage should be recorded, including the name of the medicine, the dosage and the session. We will compare the proportion of subjects using medicine and the mean days of medication use between the groups.

### Outcome measures

#### Primary outcome measures

The primary outcome of this study is the change in the NIH-CPSI total score, which will be measured from baseline to the 8th week. After we have collected data for 8 weeks, the average score from each week will be calculated.

The NIH-CPSI is a validated, self-reported questionnaire that is widely used to assess CP/CPPS patients [24, 25]. It contains 13 items that are scored in three discrete domains: pain, urinary symptoms and impact on quality of life. A score of 0 indicates that the condition described in the question never occurs.

The secondary outcome measures include the following (for the first three secondary outcomes, we will measure the change from baseline):

1. NIH-CPSI total score at the 20th and 32nd week.
2. NIH-CPSI subscale scores at the 4th, 8th, 20th, and 32nd week.
3. IPSS total score at the 4th, 8th, 20th, and 32nd week. The International Prostate Symptom Score (IPSS) is another valid, reliable and sensitive measure for patients with lower urinary tract symptoms (LUTS). The IPSS has been translated into several languages, including Chinese, and it is widely used in clinical practice and research to determine the severity of LUTS, including incomplete bladder emptying, frequency of urination, intermittency, urgency, weak urine stream, straining and nocturia [26, 27]. Each of the questions is rated from 0 (not at all) to 5 (almost always), and according to the total symptom score, the severity of LUTS can be graded as mild (0–7), moderate (8–19) or severe (20–35).
4. Global response assessment at the 4th, 8th, 20th, and 32nd week. Patients who have at least a 50% decrease compared to baseline in total NIH-CPSI score will be considered “responders”. We will compare the response rate between the two groups.
5. Expectations that acupuncture might help CP/CPPS at baseline. This scale includes four brief questions to investigate whether patients are confident that acupuncture treatment will help their CP/CPPS.
6. The degree of satisfaction for patients undergoing acupuncture treatment will be measured at the 8th, 20th, and 32nd week.

#### Table 1 Measurements at different time points

| Measurements                  | baseline | 1 week | 2 weeks | 3 weeks | 4 weeks | 5 weeks | 6 weeks | 7 weeks | 8 weeks | 20 weeks | 32 weeks |
|-------------------------------|----------|--------|---------|---------|---------|---------|---------|---------|---------|----------|----------|
| NIH-CPSI total score          | ×        | ×      | ×       | ×       | ×       | ×       | ×       | ×       | ×       | ×        | ×        |
| NIH-CPSI subscale score       | ×        | ×      | ×       | ×       | ×       | ×       | ×       | ×       | ×       | ×        | ×        |
| IPSS total score              | ×        | ×      | ×       | ×       | ×       | ×       | ×       | ×       | ×       | ×        | ×        |
| Global response assessment    | ×        | ×      | ×       | ×       | ×       | ×       | ×       | ×       | ×       | ×        | ×        |
| Degree of expectation         | ×        |        |         |         |         |         |         |         |         |          |          |
| Satisfaction                  | ×        |        |         |         |         |         |         |         |         |          |          |

NIH-CPSI: The National Institutes of Health Chronic Prostatitis Symptom Index, IPSS: International Prostate Symptom Score

---

1 needle handle, 2 needle, 3 adhesive pad, 4 blunt tip, 5 skin

**Fig. 2** Sham acupuncture used in this trial
Table 1 shows the time to visit and the data collection measurements at different time points.

Safety assessment
Adverse events (AEs) related to acupuncture treatment will be appropriately assessed and recorded by the observers throughout the trial, for instance, pain, haematoma, or nausea. AEs will be managed by acupuncturists and related clinical specialists within 24 h. The principal investigator (Z. Liu) will make the final decision to terminate the trial if severe AEs arise.

Data collection and quality control
Because nonstandard input of clinical data can contribute to the bias of results, two investigators (to assess the effect of treatment) will independently collect the data using case report forms and then input the data into a computer; this process will ensure the safety and reliability of the data. To confirm the quality of the trial, all acupuncturists will be required to have an official license and more than two years of clinical experience.

Sample size calculation and statistical analysis
The calculation of sample size was based on the primary outcome of change in NIH-CPSI total score from baseline to the 8th week of treatment (mean of 8 weeks of data). According to previous literature [12], after 10 weeks of sham acupuncture treatment, NIH-CPSI scores decreased by 6.2, with a standard deviation of 10.3. We estimated that for a 13.3-point difference in the NIH-CPSI score with a standard deviation of 4.5, and based on our clinical experience and data from previous research, the decrease in the NIH-CPSI total score should be more than 6 points (i.e., the minimal clinically important difference, MCID) [28]. Therefore, we will need to recruit 34 patients per group from Guang’anmen Hospital of Chinese Academy of Chinese Medical Sciences and Yantai Hospital of Traditional Chinese Medicine to obtain 90% power and a significance level of 5% while allowing for a 20% dropout rate.

The data will be analysed using SPSS software Ver.19.0 (IBM SPSS Statistics, IBM Corp, Somers, New York), and the data analysis will be based on the intention-to-treat (ITT) principle regarding baseline characteristics. If there are significantly more dropouts in the control group than in the treatment group, we will conduct a secondary analysis of subjects who have completed the treatment according to the protocol. The outcomes for evaluating changes between the groups will be based on the outcome of the NIH-CPSI at different time points. The significance levels will be two-sided and reported at a 5% level. For continuous measurement data, the mean, standard deviation, median and interquartile range will be represented. If the data are normally distributed, analysis of covariance will be used because the centres and baseline variables in this study are covariates that are not manipulated by the researchers but may still have an effect on the efficacy of acupuncture. If the distribution is not normal, we will use generalized estimating equations, if needed, to account for the cumulative acupuncture frequency and to observe whether increasing treatment sessions results in increased efficacy for patients. Linear regression will be used to explore whether the patients’ expectations have an impact on treatment. For categorical data, a CMH (Cochran-Mantel-Haenszel) test will be used, and the data will be represented as case and percentages. Missing data will be assumed to be missing randomly and will be imputed using multiple imputation.

Table 2 summarizes the details of the analysis methods for the primary and secondary outcomes.

Discussion
Acupuncture has been used to treat urinary diseases in China for centuries, and many RCTs have been focused on this illness [29–33]. Several RCTs to date have shown that acupuncture or electro-acupuncture is effective for CP/CPPS [12–14]; however, according to a systematic review and the consensus guidelines, positive evidence for acupuncture-based therapy in CP/CPPS remains poor [17, 34]. The lack of evidence is mainly attributable to the methodological limitations of prior studies, such as inappropriate trial designs, inadequate control groups, lack of follow-up, and lack of suitable outcome measures. Some well-designed trials have indicated that the effect of invasive sham acupuncture may be comparable to that of real acupuncture or standard drug therapy [35, 36]. These results might call into question whether the “invasive sham acupuncture” is a reasonable control for CP/CPPS or whether it is actually a type of shallow acupuncture intervention. Several researchers have also argued about whether invasive sham procedures can be incorporated by acupuncture trials [37, 38]. We are also curious about this question, and we designed the sham acupuncture to use a blunt-tip needle on acupoints without penetration. According to the findings of our prior crossover study, this non-insertion-type needle is a valid sham control for acupuncture research and can achieve good subject blinding effects with a similar appearance to traditional acupuncture [39]. Given a sufficiently thin needle and the manipulation used (lifting, thrusting or rotating), even blunt tips can make participants feel the sensation of piercing. Most of the participants were hardly able to distinguish this device from real acupuncture in the previous trial [39]. In addition, in the current trial, we will use BL 23, BL 33, BL 35 and SP 6 as the selected acupoints instead of conception vessel 1 (CV 1) and CV 4. According to our previous clinical
Table 2 Analysis methods for outcomes

| Outcomes                                      | Time frame            | Statistics                                 |
|-----------------------------------------------|-----------------------|--------------------------------------------|
| Primary outcome                               |                       |                                            |
| NIH-CPSI total score and change from baseline | baseline, week 1-8    | Covariance analysis or generalized estimating equations |
| Secondary outcomes                            |                       |                                            |
| NIH-CPSI subscales score                      | Baseline, week 4,8,20,32 | Covariance analysis or generalized estimating equations |
| NIH-CPSI total score in follow-up             | week 20,32            | Covariance analysis or generalized estimating equations |
| IPSS total score and change from baseline     | baseline, week 4,8,20,32 | Covariance analysis or generalized estimating equations |
| Global response assessment improvement        | week 4,8,20,32        | CMH test or nonparametric test             |
| Degree of expectation                         | baseline              | linear regress                             |
| Degree of satisfaction                        | week 8,20,32          | CMH test or nonparametric test             |

experiences and studies related to BPH, acupuncture on BL 23, BL 33, and BL 35 could significantly improve the condition of patients with LUTS [40]. Furthermore, the selected acupoints mentioned above are located on the participant's lower back and distal lower extremity; therefore, the participants will barely be able to see the treatment procedure and puncture wounds from their prone position. Thus, we anticipate that the acupoints chosen in this trial might increase the possibility of patient-blinding.

In this trial, we aim to clarify the efficacy and safety of acupuncture for treating CP/CPPS. We will calculate the mean NIH-CPSI scores over 8 weeks, and these scores will indicate the weekly efficacy of acupuncture during the 8 weeks of treatment; additionally, the mean value may provide more sufficient evidence for determining whether acupuncture is efficacious for treating CPPS. Furthermore, we will add an expectations scale to explore whether the patients’ expectations have a potential impact on the outcomes of acupuncture treatment. Nevertheless, this study has several limitations, including the small sample size and the unblinded acupuncturists. Due to the use of a sham acupuncture control, a relatively high rate of dropouts might be observed in the control group. Additionally, there is a risk that the blinding method may be unsuccessful in control participants, as the blunt tip needle will not leave puncture holes. Finally, a few participants might be recruited mistakenly due to the overlapping symptoms of CP/CPPS and BPH [41]. Nonetheless, the outcome assessors and patients will be blinded to decrease the potential for bias [42]. We hope that the results of this trial can provide both an evidence-based treatment option for patients suffering from CP/CPPS and an enhanced level of evidence on which to base guideline recommendations.

Acknowledgements
Not applicable.

Funding
None.

Availability of data and materials
Not applicable.

Authors' contribution
ZQ: conception, design, and manuscript writing. ZL: conception, design, and manuscript revising. ZZ: recruitment and treatment of participants during the procedure. JW: recruitment and treatment of participants during the procedure. JZ: data collection and analysis. All authors approved the publication of this protocol.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The Research Ethical Committee of Guang’anmen Hospital of China Academy of Chinese Medical Sciences and Yantai Hospital of Traditional Chinese Medicine have approved this trial protocol. No individual clinical data will be presented in this article.

Author details
1Department of Acupuncture, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China. 2Beijing University of Chinese Medicine, Beijing 100029, China. 3Department of Acupuncture, Yantai Hospital of Traditional Chinese Medicine, Yantai 265200, China.

Received: 31 January 2016 Accepted: 29 October 2016
Published online: 07 November 2016

References
1. Krieger JN, Riley DE, Cheah PY, Liong ML, Yuen KH. Epidemiology of prostatitis: new evidence for a world-wide problem. World J Urol. 2003;21:70–4.
2. Nickel JC, Downey J, Hunter D, Clark J. Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. J Urol. 2001;165:842–5.
3. Clemens JQ, Meenan RT, O’Keefe-Rosetti MC, Gao SY, Brown SO, Calhoun EA. Prevalence of prostatitis-like symptoms in a managed care population. J Urol. 2006;176:593–6.
4. Liang CA, Li HJ, Wang ZP, Xing JP, Hu WL, Zhang TF, et al. The prevalence of prostatitis-like symptoms in China. J Urol. 2009;182:558–63.
5. Rees J, Abraham M, Doble A, Cooper A. Diagnosis and treatment of chronic bacterial prostatitis and chronic pelvic pain syndrome: a consensus guideline. BJU Int. 2015;116:509–25.
6. Schaeffer AJ. Etiology and management of chronic pelvic pain syndrome in men. Urology. 2004;63 Suppl 1:75–84.
7. Yang Q, Wei Q, Li H, Yang Y, Zhang S, Dong Q. The effect of alpha-adrenergic antagonists in prostatitis/chronic pelvic pain syndrome: a meta-analysis of randomized controlled trials. J Androl. 2006;27:847–52.
8. Anothaisintawee T, Attia J, Nickel JC, Thamnakrison S, Numfawaj P, McEvoy M, et al. Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis. JAMA. 2011;305:78–86.
9. Nickel JC, Baranowski AP, Pontari M, Berger RE, Tripp DA. Management of men diagnosed with chronic prostatitis/chronic pelvic pain syndrome who have failed traditional management. Rev Urol. 2007;9:63–72.
10. Anderson RU, Wise D, Sawyer T, Chan C. Integration of myo-fascial trigger point release and paradoxical relaxation training treatment of chronic pelvic pain in men. J Urol. 2005;174:155–60.
11. Lee SH, Lee BC. Use of acupuncture as a treatment method for chronic prostatitis/chronic pelvic pain syndrome. Curr Urol Rep. 2011;12:288–96.
12. Lee SW, Long ML, Yuen HK, Krieger JN. Acupuncture versus sham acupuncture for chronic prostatitis/chronic pelvic pain. Am J Med. 2011;129:1–7.
13. Lee SH, Lee BC. Electroacupuncture relieves pain in men with chronic prostatitis/chronic pelvic pain syndrome: three-arm randomized trial. Urology. 2009;73:1036–41.
14. Sahin S, Bicer M, Eren GA, Tas S, Tugcu V, Tasci AI, et al. Acupuncture relieves symptoms in chronic prostatitis/chronic pelvic pain syndrome: a randomized, sham-controlled trial. Prostate Cancer Prostatic Dis. 2015;18:249–54.
15. Kucuk EY, Soyekmen FY, Binday A, Boylu U, Onol FF, Guvenc E. Effectiveness of acupuncture on chronic prostatitis/chronic pelvic pain syndrome category IIIb patients: a prospective, randomized, nonblinded, clinical trial. Urology. 2015;85:636–40.
16. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. BMJ. 2013;346:e7586.
17. Krieger JN, Hyberg L, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999;282:236–7.
18. Nickel JC, Shoskes D, Wang Y, Alexander RB, Fowler Jr JE, Zeitlin S, et al. How does the pre-massage and post massage 2-glass test compare to the Meares-Staney 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome? J Urol. 2006;176:119–24.
19. Xie H. Huangdi Neijing. Publishing House of Ancient Chinese Medical books. 2001.
20. Yuan SY, Qin Z, Liu DS, Yin WQ, Zhang ZL, Li SG. Acupuncture for chronic pelvic pain syndromes (CPPS) and its effect on cytokines in prostatic fluid. Zhongguo Zhen Jiu. 2011;31:11–4.
21. Siegel S, Paszkiewicz E, Kirkpatrick C, Hinkel B, Oleson K. Sacral nerve stimulation in patients with chronic intractable pelvic pain. J Urol. 2001;166:1742–5.
22. Chen R, Nickel JC. Acupuncture ameliorates symptoms in men with chronic prostatitis/chronic pelvic pain syndrome. Urology. 2003;61:1156–9.
23. Streitberger K, Kleinhenn J. Introducing a placebo needle into acupuncture research. Lancet. 1998;352:364–5.
24. Hong K, Xu QQ, Jiang H, Wang XF, Zhu JC. Chronic Prostatitis Symptom Index of Chinese. Zhonghua Nan Ke Xue. 2002;38:41–48.
25. Linde K, Streng A, Jürgens S, Hoppe A, Brinkhaus B, Witt C, et al. Efficacy of acupuncture for the prophylaxis of migraine: a multicenter randomized controlled clinical trial. Lancet Neurol. 2006;5:310–6.
26. Birch S. A review and analysis of placebo treatments, placebo effects and placebo controls in trials of medical procedures when sham is not inert. J Altern Complement Med. 2006;12:303–10.
27. Vickers AJ. Placebo controls in randomized trials of acupuncture. Eval Health Profess. 2002;25:413–33.
28. Liu B, Xu H, Ma R, Mo Q, Yan S, Liu Z. Effect of blinding with a new pragmatic placebo needle: a randomized controlled crossover study. Medicine. 2014;93:e200.
29. Wang Y, Liu B, Yu J, Wu J, Jiang L, Liu Z. Electroacupuncture for moderate and severe benign prostatic hyperplasia: a randomized controlled trial. PLoS ONE. 2013;8:e59449.
30. Nickel JC. The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis. Curr Opin Urol. 2006;16:15–7.
31. Altman DG, Dore CJ. Randomisation and baseline comparisons in trials of medical procedures when sham is not inert. J Altern Complement Med. 2002;8:162–72.
32. Altman DG, Dore CJ, Randomisation and baseline comparisons in clinical trials. Lancet. 1990;335:149–53.